(Q43984497)

28 November 2017

title

Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension (English)

1 reference

28 November 2017

Marta Pombo Jiménez

1

1 reference

28 November 2017

Pilar Escribano Subías

2

1 reference

28 November 2017

Rocío Tello de Meneses

3

1 reference

28 November 2017

Miguel Angel Gómez-Sánchez

4

1 reference

28 November 2017

Juan Delgado Jiménez

5

1 reference

28 November 2017

Regina Dalmau González-Gallarza

6

1 reference

28 November 2017

María Lázaro Salvador

7

1 reference

28 November 2017

Isidro Hernández Rodríguez

8

1 reference

28 November 2017

Juan Tascón Pérez

9

1 reference

28 November 2017

Carlos Sáenz de la Calzada

10

1 reference

28 November 2017

language of work or name

Spanish

0 references

publication date

1 March 2003

1 reference

Revista Española de Cardiología

28 November 2017

published in

1 reference

28 November 2017

volume

56

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

230-235

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Treatment of Severe Pulmonary Hypertension Secondary to Connective Tissue Diseases With Continuous IV Epoprostenol (Prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2803%2976858-4

7 January 2021

10.1016/S0300-8932(03)76858-4

Identifiers

DOI

1 reference

28 November 2017

1 reference